ADAR1 Capital Management LLC Purchases New Shares in Savara Inc. $SVRA

Key Points

• ADAR1 Capital Management acquired 1.4 million Savara shares worth approximately $8.65 million, representing about 0.68% of the company. Institutional investors and hedge funds collectively own 87.93% of SVRA.
• Analyst sentiment is mixed but leans positive, with an overall “Moderate Buy” rating and an average price target of $10.14; ratings include one Strong Buy, six Buys and one Sell.
• Savara reported a quarterly loss of $0.16 per share, missing the $0.14 consensus estimate. Its stock opened at $5.60, while the company continues developing Molgradex for the rare lung disease autoimmune pulmonary alveolar proteinosis.

ADAR1 Capital Management LLC acquired a new stake in Savara Inc. (NASDAQ:SVRA - Free Report) during the second quarter, according to its most recent disclosure with the SEC. The institutional investor acquired 1,403,409 shares of the company's stock, valued at approximately $8,645,000. ADAR1 Capital Management LLC owned approximately 0.68% of Savara at the end of the most recent reporting period.

A number of other hedge funds and other institutional investors also recently modified their holdings of SVRA. Prudential Financial Inc. acquired a new position in shares of Savara during the 2nd quarter worth approximately $30,000. BNP Paribas Financial Markets increased its stake in Savara by 52.3% during the 2nd quarter. BNP Paribas Financial Markets now owns 13,473 shares of the company's stock worth $31,000 after acquiring an additional 4,626 shares during the period. Brevan Howard Capital Management LP acquired a new position in Savara in the 2nd quarter valued at $33,000. Russell Investments Group Ltd. raised its holdings in Savara by 930.5% in the 3rd quarter. Russell Investments Group Ltd. now owns 10,480 shares of the company's stock valued at $37,000 after acquiring an additional 9,463 shares in the last quarter. Finally, CIBC Bancorp USA Inc. acquired a new position in Savara in the 3rd quarter valued at $44,000. Institutional investors and hedge funds own 87.93% of the company's stock.

Wall Street Analysts Forecast Growth

Several research firms have recently issued reports on SVRA. Weiss Ratings reissued a "sell (d-)" rating on shares of Savara in a report on Friday, July 17th. Wall Street Zen cut shares of Savara from a "hold" rating to a "sell" rating in a research report on Saturday, August 15th. One research analyst has rated the stock with a Strong Buy rating, six have issued a Buy rating and one has issued a Sell rating to the company. Based on data from MarketBeat.com, Savara currently has an average rating of "Moderate Buy" and an average target price of $10.14.

Savara Price Performance

Savara stock opened at $5.60 on Wednesday. The company has a debt-to-equity ratio of 0.21, a quick ratio of 10.13 and a current ratio of 10.13. Savara Inc. has a 52 week low of $3.10 and a 52 week high of $7.01. The stock has a market capitalization of $1.15 billion, a P/E ratio of -9.66 and a beta of 0.29. The stock has a fifty day moving average of $5.70 and a 200-day moving average of $5.48.

Savara (NASDAQ:SVRA - Get Free Report) last released its earnings results on Tuesday, August 11th. The company reported ($0.16) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.14) by ($0.02). On average, sell-side analysts expect that Savara Inc. will post -0.62 earnings per share for the current fiscal year.

Savara Company Profile

Savara Inc NASDAQ: SVRA is a clinical-stage biopharmaceutical company focused on developing and commercializing therapies for rare respiratory diseases. The company specializes in in-licensing, advancing and potentially bringing to market novel treatments that address severe pulmonary conditions with high unmet medical need.

The company's lead candidate, Molgradex (recombinant human granulocyte-macrophage colony-stimulating factor, or GM-CSF), is under regulatory review for the treatment of autoimmune pulmonary alveolar proteinosis (PAP), a rare lung disease characterized by the accumulation of surfactant.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Continue following MarketBeat

Add MarketBeat as your preferred source on Google to see our latest stories in your feed.

Add As Preferred Source